Cilostazol

SKU: orb1310589

Description

Cilostazol (OPC 21) is a selective phosphodiesterase 3 (PDE3) inhibitor. It is widely used in research to study vasodilation, inhibition of platelet aggregation, and cellular proliferation in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 73963-72-1
• MW: 369.46
• Purity: 99.90% (May vary between batches)
• Formula: C₂₀H₂₇N₅O₂
• SMILES: C(CCCOC=1C=C2C(=CC1)NC(=O)CC2)C=3N(N=NN3)C4CCCCC4
• Target: PDE,Autophagy
• Solubility: DMSO:15 mg/mL (40.6 mM);Ethanol:3.7 mg/mL (10.01 mM);10% DMSO+90% Corn Oil:1.5 mg/mL (4.06 mM)

Bioactivity

• Target IC50:
  PDE3:0.2 μM
• In Vivo:
  Cilostazol induces relaxation of vascular smooth muscle and causes vasodilation. It inhibits the expression of monocyte chemotactic protein-1 (MCP-1) induced by cytokines. Additionally, Cilostazol reduces plasma triglycerides and increases high-density lipoprotein (HDL) levels. The vasodilatory and antithrombotic effects of Cilostazol are primarily due to the inhibition of phosphodiesterase 3 (PDE3) and the subsequent elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. It also inhibits platelet aggregation and adenosine uptake.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cilostazol, Autophagy, cardiovascular, fibrogenesis, hepatic, Inhibitor, injury, late, inhibit, PDE3, OPC21, OPC-21, OPC13013, OPC-13013, OPC 21, OPC 13013, phosphodiesterase, Phosphodiesterase (PDE)

Compound Identifiers

PubChem CID

2754